Immunohistochemical comparison of three programmed death-ligand 1 (PD-L1) assays in triple-negative breast cancer.

por Katsuhiro Yoshikawa, Mitsuaki Ishida, Hirotsugu Yanai, Koji Tsuta, Mitsugu Sekimoto, Tomoharu Sugie
Publicado 2021

Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients.

por Katsuhiro Yoshikawa, Mitsuaki Ishida, Hirotsugu Yanai, Koji Tsuta, Mitsugu Sekimoto, Tomoharu Sugie
Publicado 2021

Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug

por Yoshimasa Tanaka, Masashi Iwasaki, Kaoru Murata-Hirai, Kenji Matsumoto, Kosuke Hayashi, Haruki Okamura, Tomoharu Sugie, Nagahiro Minato, Craig T. Morita, Masakazu Toi
Publicado 2017